Skip to main content
main-content

01.12.2014 | Laboratory Investigation | Ausgabe 3/2014

Journal of Neuro-Oncology 3/2014

Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models

Zeitschrift:
Journal of Neuro-Oncology > Ausgabe 3/2014
Autoren:
Kaijun Di, Stephen T. Keir, Daniela Alexandru-Abrams, Xing Gong, Howard Nguyen, Henry S. Friedman, Daniela A. Bota
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s11060-014-1579-y) contains supplementary material, which is available to authorized users.

Abstract

Retaspimycin hydrochloride (IPI-504), an Hsp90 (heat shock protein 90) inhibitor, has shown activity in multiple preclinical cancer models, such as lung, breast and ovarian cancers. However, its biological effects in gliomas and normal brain derived cellular populations remain unknown. In this study, we profiled the expression pattern of Hsp90α/β mRNA in stable glioma cell lines, multiple glioma-derived primary cultures and human neural stem/progenitor cells. The effects of IPI-504 on cell proliferation, apoptosis, motility and expression of Hsp90 client proteins were evaluated in glioma cell lines. In vivo activity of IPI-504 was investigated in subcutaneous glioma xenografts. Our results showed Hsp90α and Hsp90β expression levels to be patient-specific, higher in high-grade glioma-derived primary cells than in low-grade glioma-derived primary cells, and strongly correlated with CD133 expression and differentiation status of cells. Hsp90 inhibition by IPI-504 induced apoptosis, blocked migration and invasion, and significantly decreased epidermal growth factor receptor levels, mitogen-activated protein kinase and/or Akt activities, and secretion of vascular endothelial growth factor in glioma cell lines. In vivo study showed that IPI-504 could mildly attenuate tumor growth in immunocompromised mice. These findings suggest that targeting Hsp90 by IPI-504 has the potential to become an active therapeutic strategy in gliomas in a selective group of patients, but further research into combination therapies is still needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOC 67 kb)
11060_2014_1579_MOESM1_ESM.doc
Supplementary material 2 (DOC 38 kb)
11060_2014_1579_MOESM2_ESM.doc
Supplementary material 3 (PDF 116 kb)
11060_2014_1579_MOESM3_ESM.pdf
Supplementary material 4 (PDF 234 kb)
11060_2014_1579_MOESM4_ESM.pdf
Supplementary material 5 (PDF 175 kb)
11060_2014_1579_MOESM5_ESM.pdf
Supplementary material 6 (DOC 36 kb)
11060_2014_1579_MOESM6_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2014

Journal of Neuro-Oncology 3/2014 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise